JP2010513513A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513513A5
JP2010513513A5 JP2009542895A JP2009542895A JP2010513513A5 JP 2010513513 A5 JP2010513513 A5 JP 2010513513A5 JP 2009542895 A JP2009542895 A JP 2009542895A JP 2009542895 A JP2009542895 A JP 2009542895A JP 2010513513 A5 JP2010513513 A5 JP 2010513513A5
Authority
JP
Japan
Prior art keywords
composition
disease
biological agent
seq
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513513A (ja
JP5452230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/025956 external-priority patent/WO2008082563A2/en
Publication of JP2010513513A publication Critical patent/JP2010513513A/ja
Publication of JP2010513513A5 publication Critical patent/JP2010513513A5/ja
Application granted granted Critical
Publication of JP5452230B2 publication Critical patent/JP5452230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542895A 2006-12-21 2007-12-19 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物 Expired - Fee Related JP5452230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87629206P 2006-12-21 2006-12-21
US60/876,292 2006-12-21
PCT/US2007/025956 WO2008082563A2 (en) 2006-12-21 2007-12-19 Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013016463A Division JP2013079288A (ja) 2006-12-21 2013-01-31 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物

Publications (3)

Publication Number Publication Date
JP2010513513A JP2010513513A (ja) 2010-04-30
JP2010513513A5 true JP2010513513A5 (enExample) 2010-12-09
JP5452230B2 JP5452230B2 (ja) 2014-03-26

Family

ID=39523820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009542895A Expired - Fee Related JP5452230B2 (ja) 2006-12-21 2007-12-19 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
JP2013016463A Withdrawn JP2013079288A (ja) 2006-12-21 2013-01-31 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013016463A Withdrawn JP2013079288A (ja) 2006-12-21 2013-01-31 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物

Country Status (7)

Country Link
US (4) US20100184659A1 (enExample)
EP (1) EP2120859B1 (enExample)
JP (2) JP5452230B2 (enExample)
AU (1) AU2007339280B2 (enExample)
CA (1) CA2671925A1 (enExample)
ES (1) ES2447516T3 (enExample)
WO (1) WO2008082563A2 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
EP2282763B1 (en) * 2008-04-07 2013-12-11 National Institute Of Immunology Process for preparing supramolecular calcitonin assemblies (SCA)
JP5599778B2 (ja) 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
WO2011031856A1 (en) * 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2838059C (en) 2011-06-03 2020-08-25 Maguire Abbey, Llc Method, composition, and articles for improving joint lubrication
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US20160022379A1 (en) * 2014-07-23 2016-01-28 Duane C. Keller Assemblies For Improved Periodontal Surgery And Recovery Therefrom
US20180271970A1 (en) 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
PE20181531A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacuna del virus herpes simple
SMT202200310T1 (it) 2015-12-23 2022-09-14 Modernatx Inc Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CN109310680B (zh) 2016-06-30 2022-11-01 度瑞公司 长效配制物
US10866003B2 (en) 2017-04-14 2020-12-15 Johnson Controls Technology Company Thermostat with preemptive heating, cooling, and ventilation in response to elevated occupancy detection via proxy
CN110997708A (zh) 2017-04-27 2020-04-10 礼来公司 人bmp7蛋白的变体
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
JP7424976B2 (ja) 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (fr) 2018-09-02 2021-07-14 Modernatx Inc Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
US12644102B2 (en) 2018-09-13 2026-06-02 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex E1-α, E1-β, and E2 subunits for the treatment of maple syrup urine disease
JP2022500436A (ja) 2018-09-13 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. 糖原病を処置するためのグルコース−６−ホスファターゼをコードするポリヌクレオチド
MA53615A (fr) 2018-09-14 2021-07-21 Modernatx Inc Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
WO2020069169A1 (en) 2018-09-27 2020-04-02 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
US11324806B2 (en) 2018-10-19 2022-05-10 Warsaw Orthopedic, Inc. Sustained delivery of a growth differentiation factor
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
WO2020227642A1 (en) 2019-05-08 2020-11-12 Modernatx, Inc. Compositions for skin and wounds and methods of use thereof
EP3987027A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonuclease-resistant messenger rna and uses thereof
MA56517A (fr) 2019-06-24 2022-04-27 Modernatx Inc Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
AU2021285812A1 (en) 2020-06-01 2023-01-05 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
JP2023533174A (ja) 2020-06-12 2023-08-02 ユニバーシティ オブ ロチェスター ＡＣＥ－ｔＲＮＡのコード化及び発現
CA3199784A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20240189449A1 (en) 2021-03-24 2024-06-13 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022240806A1 (en) 2021-05-11 2022-11-17 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
AU2023215397A1 (en) 2022-02-07 2024-08-22 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression.
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4562163A1 (en) 2022-07-26 2025-06-04 ModernaTX, Inc. Engineered polynucleotides for temporal control of expression
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024178172A1 (en) 2023-02-23 2024-08-29 University Of Rochester Agents and methods for making closed-end dna thread molecules
WO2024182301A2 (en) 2023-02-27 2024-09-06 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
CN116270436A (zh) * 2023-03-30 2023-06-23 上海瑞凝生物科技有限公司 一种疏水液晶凝胶及其制备方法和应用
EP4704816A1 (en) 2023-05-03 2026-03-11 ModernaTX, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025101685A1 (en) 2023-11-09 2025-05-15 University Of Rochester Suppression of nonsense mutations using anticodon engineered (ace)-trnas
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
WO2026006151A2 (en) 2024-06-24 2026-01-02 University Of Rochester Functionalization of ace-trna encoding synthetic linear picovectors
WO2026030209A1 (en) 2024-07-29 2026-02-05 University Of Rochester Use of decoding trnas to boost protein expression or function
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en) 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use
WO2026112050A2 (en) 2024-11-21 2026-05-28 Modernatx, Inc. Claudin 6 binding molecules, nucleic acids encoding same, and methods of use
WO2026122882A2 (en) 2024-12-06 2026-06-11 Modernatx, Inc. Solid tumor t cell engagers and uses thereof
WO2026151698A1 (en) 2025-01-07 2026-07-16 Modernatx, Inc. Lag3 binding molecules, nucleic acids encoding same, and methods of use
WO2026155976A1 (en) 2025-01-14 2026-07-23 Modernatx, Inc. Pd-1 binding proteins, nucleic acids encoding same, and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
AU666291B2 (en) 1990-06-15 1996-02-08 Carnegie Institution Of Washington Gdf-1
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
CA2129820C (en) 1992-02-12 2003-06-17 Helge Neidhardt Dna sequences encoding novel growth/differentiation factors
WO1994010203A2 (en) 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Op-3-induced morphogenesis
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
WO1994015966A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-9
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
JPH09503903A (ja) 1993-07-09 1997-04-22 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−６
EP0725796A4 (en) 1993-10-08 1999-12-01 Univ Johns Hopkins Growth differentiation factor-10
JP3300500B2 (ja) 1993-10-12 2002-07-08 新日本製鐵株式会社 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
PT840748E (pt) * 1995-07-25 2003-08-29 Novartis Ag Cristais de factor de crescimento transformante beta
AU6267798A (en) * 1997-02-07 1998-08-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
IL156682A0 (en) * 2000-12-29 2004-01-04 Pbl Biomedical Lab Controlled release systems for polymers
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
ME00509B (me) * 2002-09-27 2011-10-10 Zentaris Gmbh Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje
KR20050094832A (ko) * 2002-12-31 2005-09-28 알투스 파마슈티컬스 인코포레이티드 단백질 결정과 이온성 중합체를 함유하는 복합체
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
CA2567405A1 (en) 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
ATE543833T1 (de) 2005-12-22 2012-02-15 Janssen Biotech Inc Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen

Similar Documents

Publication Publication Date Title
US12173040B2 (en) Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis
AU771382B2 (en) Methods and compositions for healing and repair of articular cartilage
US8101676B2 (en) Osteogenic paste compositions and uses thereof
Vukičević et al. Discovery and clinical applications of bone morphogenetic proteins
JP2001505097A (ja) 改良された軟骨誘導活性および／または硬骨誘導活性を有する複合体
JP2006502971A (ja) 結合組織刺激ペプチド
JP2005536244A (ja) シーラントもしくは組織生成製品
JP2013518808A (ja) 骨形成タンパク質のｐＨを制御するための緩衝液
EP1148897B1 (en) Methods and compositions for healing and repair of articular cartilage
US20050244393A1 (en) Sealant or tissue generating product
CN101249278A (zh) 骨诱导材料及其制备方法和应用
KR100704537B1 (ko) 관절 연골의 치유 및 회복을 위한 조성물
JP2012517483A5 (enExample)
Saito et al. Effect of phosphophoryn on rhBMP-2-induced bone formation
CN102822197A (zh) 具有降低的免疫原性的bmp-7变体
MX2009013369A (es) Ingenieria de tejidos para la formacion de cemento radicular, hueso, dentina, cartilago y ligamento periodontal mediante la utilizacion de la proteina humana del cemento 1 (cemp-1).
SAITO et al. Dentin phosphophoryn accelerates rhBMP-2/HAP-induced bone formation
FR2933305A1 (fr) Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un matrice organique